Last reviewed · How we verify
Mycocten (ethyl hydroxybenzoate)
Mycocten (generic name: ethyl hydroxybenzoate) is a Standardized Chemical Allergen drug. It is currently in unknown development.
Mycocten works by binding to estrogen receptor beta, which is a protein that plays a role in various cellular processes.
Mycocten (ethyl hydroxybenzoate) is a small molecule standardized chemical allergen that targets the estrogen receptor beta. Its mechanism of action is not well-documented, and it is not FDA-approved for any indications. As a result, there is limited information available on its commercial status, safety considerations, or pharmacokinetic properties. Further research is needed to fully understand the potential benefits and risks of Mycocten. Its development history is also unclear.
At a glance
| Generic name | ethyl hydroxybenzoate |
|---|---|
| Drug class | Standardized Chemical Allergen |
| Target | Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14 |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of estrogen receptors like locks on a door. Mycocten is a key that fits into one of these locks, which can affect how cells behave. By binding to estrogen receptor beta, Mycocten may influence the activity of genes that are involved in various physiological processes.
Approved indications
Common side effects
Key clinical trials
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- ASCEND: A Study of Cardiovascular Events iN Diabetes (PHASE4)
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (PHASE4)
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- Safe Excipient Exposure in Neonates and Small ChildreN
- Anesthetics in Rhytidoplasty - A Comparison Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycocten CI brief — competitive landscape report
- Mycocten updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Mycocten
What is Mycocten?
How does Mycocten work?
What is the generic name of Mycocten?
What drug class is Mycocten in?
What development phase is Mycocten in?
What does Mycocten target?
Related
- Drug class: All Standardized Chemical Allergen drugs
- Target: All drugs targeting Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 14
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing